ATYR — Stock Film
STOCK FILMSCENE 1/11ATYR · $0.50
Stock Expert AI presents
ATYR
aTyr Pharma, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
aTyr Pharma, Inc. A quick introduction.

It operates in the world of health and science. It has 58 employees. Now — the numbers.

58 employees
$46.6M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $391.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 74% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$0
2021
$10.4M
2022
$353K
2023
$235K
2024
$190K
2025
In the vault right now:
$0
DEBT: $12.0M
At this pace, that money lasts about 1.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
6
very weak

Clearly below the class average.

FINANCIAL STRENGTH
36
weak

Clearly below the class average.

VALUATION
6
very weak

Clearly below the class average.

GROWTH
23
very weak

Clearly below the class average.

PRICE MOMENTUM
14
very weak

Clearly below the class average.

WORTH WATCHING

Business Quality: Profit power and business quality trail similar companies in the sector.

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 3 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
The stock has lost its spark0/10
Each sale is made at a loss3/10
Costs eat into the margin4/10
WORTH WATCHING

Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 92% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Executives are buying their own stock

Over the last 12 months, company executives reported 21 buys and 6 sells. Management buying with its own money is usually read as a good sign.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $5.13920% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $74.1M against $190K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/3
Trading under $1

The stock sits at $0.50. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.

3
THE RISKS · 3/3
The cash has a countdown

At the current pace of spending, the cash lasts about 1.1 years. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, ATYR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: ATYR is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

Analysts’ average target sits above today’s price, yet the valuation grade (6/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film